Ellicott City, MD, United States of America

Sangeeta Ray

USPTO Granted Patents = 26 (Patent Applications = 22)

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 12 (Patent Applications = 16)

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 110(Granted Patents)

Company Filing History:

25 out of 3,682

The Johns Hopkins University

Northwestern University

patents

4. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12233137 - PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy (2025-02-25),

2. 12065413 - PSMA targeted fluorescent agents for image guided surgery (2024-08-20),

3. 11911488 - Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy (2024-02-27),

4. 11871895 - Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo (2024-01-16),

5. 11814365 - PSMA targeted fluorescent agents for image guided surgery (2023-11-14),

6. 11813340 - PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy (2023-11-14),

7. 11661402 - PSMA-targeting compounds and uses thereof (2023-05-30),

8. 11478558 - Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer (2022-10-25),

9. 11458213 - Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer (2022-10-04),

10. 11078166 - Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof (2021-08-03),

11. 11021450 - PSMA targeted fluorescent agents for image guided surgery (2021-06-01),

12. 10857246 - Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof (2020-12-08),

13. 10736974 - Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy (2020-08-11),

14. 10717750 - 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents (2020-07-21),

15. 10688198 - Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen and uses thereof (2020-06-23),

Title: The Innovative Contributions of Sangeeta Ray in Cancer Radiotherapy

Introduction

Sangeeta Ray, based in Ellicott City, MD, is a prominent inventor with an impressive portfolio of 26 patents. His groundbreaking work primarily focuses on advancements in cancer radiotherapy, particularly targeting prostate cancer through innovative compounds and techniques.

Latest Patents

Among Sangeeta Ray's latest patents are the following notable inventions:

1. **PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates for Cancer Radiotherapy** - This patent discloses small molecule radiohalogenated PSMA inhibitors and metal complexes designed for use in radioimaging and radiotherapy, targeting PSMA-related diseases, including prostate cancer. It also details the combination of these inhibitors with a competitive PSMA ligand to reduce off-target accumulation, enhancing treatment efficacy.

2. **PSMA Targeted Fluorescent Agents for Image Guided Surgery** - This invention reveals compositions and methods for visualizing tissue using near-infrared radiation. It includes compounds consisting of near-infrared, closed chain, sulfo-cyanine dyes, and prostate-specific membrane antigen ligands, offering potential improvements in surgical precision.

Career Highlights

Sangeeta Ray's career is distinguished by his work at reputable institutions such as The Johns Hopkins University and Duke University. His contributions in these roles have not only furthered the field of cancer treatment but also significantly impacted research methodologies related to radiotherapy and imaging techniques.

Collaborations

Throughout his career, Sangeeta has collaborated with esteemed professionals such as Martin Gilbert Pomper and Ronnie Charles Mease. These partnerships have facilitated the exchange of innovative ideas and technical expertise, leading to advancements that enhance the effectiveness of cancer treatments.

Conclusion

Sangeeta Ray's innovative spirit and dedication to research in cancer radiotherapy have positioned him as a key figure in the field. With 26 patents to his name, his work continues to inspire and pave the way for new treatment options for patients battling prostate cancer and other PSMA-related diseases.

This text is generated by artificial intelligence and may not be accurate.